domingo, 26 de julio de 2026
Engineered probiotic bacteria boost immune attack against pancreatic cancer
https://www.news-medical.net/news/20260724/Engineered-probiotic-bacteria-boost-immune-attack-against-pancreatic-cancer.aspx
Cancer immunotherapies have transformed treatment for many cancers, but pancreatic cancer remains especially difficult to treat. One major reason is that pancreatic tumors often create a "cold" tumor microenvironment, where the tumor prevents immune cells from mounting a strong attack.
Evidence shows artificial sweeteners cannot be judged as a single group
https://www.news-medical.net/news/20260723/Evidence-shows-artificial-sweeteners-cannot-be-judged-as-a-single-group.aspx
A review of seven sweeteners and mixed exposures shows why dose, formulation, diet, and individual biology matter when interpreting their potential effects on the gut and metabolism.
A recent narrative review in the journal Nutrients synthesized the effects of seven individual non-nutritive artificial sweeteners (NASs) and mixed NAS exposures on gut microbiota composition and host metabolic health and developed an interactive knowledge graph to organize and navigate the available evidence.
Our twenty-five year journey The Lancet Infectious Diseases +...
Our twenty-five year journey
The Lancet Infectious Diseases
https://www.thelancet.com/journals/laninf/issue/vol26no8/PIIS1473-3099(26)X2007-2
GLP-1/GIP agonists and cancer: mechanisms, evidence, and nutrition implications Sedat Arslan* [1] , Ayca Aydin [2] + +...
https://www.academia.edu/2998-7741/3/2/10.20935/AcadOnco8234
Obesity and diabetes increase cancer risk through insulin resistance, chronic inflammation, and altered growth signaling. Glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists reshape this metabolic milieu and are increasingly used for weight loss and glycemic control. Uncertainty persists about whether these agents influence cancer incidence or progression, and there is no consensus on nutrition care during therapy. We present a narrative, mechanism-to-clinic review that synthesizes randomized and observational human studies alongside translational evidence on insulin/IGF-1 pathways, adipokines, bile acids, and the microbiota. We also integrate practice-focused guidance on preserving lean mass, monitoring micronutrients, and managing gastrointestinal tolerance while on these agents. Current human evidence does not show a consistent increase in overall cancer risk with these therapies; however, signals are heterogeneous across tumor sites and follow-up remains limited. Randomized trials rarely adjudicate cancer outcomes, and pharmacovigilance and preclinical results are mixed and context-dependent. Weight loss and improved insulin sensitivity plausibly reduce pro-tumorigenic signaling, whereas rapid weight reduction may threaten muscle mass unless accompanied by proactive nutrition support and resistance exercise. Available data suggest no uniform carcinogenic signal from GLP-1/GIP therapies to date, but organ-specific effects and long-term safety require rigorous, adequately powered follow-up. Dietitians and oncology teams should co-manage patients using high-quality protein distributed across meals, fiber-rich, low-glycemic dietary patterns (such as Mediterranean-style eating), resistance exercise, and targeted micronutrient monitoring, alongside standardized recording of cancer-relevant outcomes.
https://www.academia.edu/journals/academia-oncology/articles?source=journal-top-nav
Suscribirse a:
Entradas (Atom)
.png)
